Tirzepatide (LY3298176) is a dual GLP-1/GIP receptor agonist and tool compound in metabolism research. Compare it to semaglutide and retatrutide and verify HPLC/ESI-MS lots.
Tirzepatide (development code LY3298176) is a synthetic peptide that co-activates the GLP-1 and GIP receptors, placing it at the center of modern incretin and metabolism research. Because approved medicines containing tirzepatide are widely recognized, it is also one of the most frequently sourced reference compounds in research catalogs. This overview summarizes its profile, how it differs from semaglutide and retatrutide, and how to verify a lot before buying.
Research status. Tirzepatide itself is an active ingredient in approved prescription medicines, but the lyophilized material sold by Peplxa is labeled and supplied for qualified in-vitro laboratory research only. It is not a consumer treatment and no dosing guidance is provided.
What is tirzepatide?
Incretins are gut hormones that influence glucose-dependent insulin signaling and energy balance. GLP-1 receptor agonists are an established class; tirzepatide extends that pharmacology by also engaging the glucose-dependent insulinotropic polypeptide (GIP) receptor. Researchers use it to study the combined effects of dual incretin receptor activation rather than GLP-1 signaling alone.
Tirzepatide vs semaglutide vs retatrutide
| Compound | Receptor profile | Class | Typical research role |
|---|---|---|---|
| Semaglutide | GLP-1 | Single agonist | Long-acting GLP-1 reference |
| Tirzepatide | GLP-1 + GIP | Dual agonist | Dual-incretin reference compound |
| Retatrutide | GLP-1 + GIP + glucagon | Triple agonist | Frontier multi-receptor research |
The earlier once-daily liraglutide is commonly used as an additional comparator. Sourcing the full series from one supplier keeps labeling, documentation and lot format consistent across an experiment.
Why researchers study tirzepatide
- Dual-incretin pharmacology. It provides a practical tool for studying GIP signaling alongside the better-characterized GLP-1 pathway.
- A large evidence base. The SURMOUNT and SURPASS clinical programs generated an extensive public literature, giving researchers a rich reference set for mechanistic and comparative work.
- A benchmark for newer molecules. Dual and triple agonists are routinely evaluated against tirzepatide, making it a near-essential catalog compound for metabolism laboratories.
Verifying a tirzepatide lot
Tirzepatide is a large peptide, so identity testing matters as much as purity. Before ordering, confirm that the supplier provides:
- Reverse-phase HPLC with the target peak area-percent purity and an attached trace.
- ESI-MS identity with an observed mass consistent with the theoretical molecular mass of tirzepatide.
- Matched lot numbers between the Certificate of Analysis and the vial label.
Peplxa's release workflow is documented on the testing method page, and each record is retrievable by compound on the Lot Records page. For sensitive cell work, ask about endotoxin screening before designing the assay.
Storage and handling (laboratory notes)
Material is supplied freeze-dried in sealed glass vials and should be kept frozen near -20°C, protected from light. If a protocol calls for reconstitution, use sterile diluent, run it slowly down the vial wall and roll gently — never vortex. Refrigerate reconstituted material at 2-8°C and use promptly. Concentrations and protocols are the researcher's responsibility; Peplxa does not advise on them.
Sourcing
Follow the supplier checks in the online buying guide and inspect the batch record before purchase. The tirzepatide product page lists current box specifications and links the lot record; related compounds are grouped under the weight-loss research category, and the triple-agonist profile is covered in the retatrutide overview.
